Assessing Altria (MO) Valuation After FDA Clears New on! PLUS Smoke‑Free Nicotine Products
Altria Group (MO) just cleared an important regulatory hurdle, with the FDA granting marketing authorization for six on! PLUS nicotine pouch products from its Helix Innovations unit, potentially reshaping how investors think about its long term smoke free pivot.
See our latest analysis for Altria Group.
Even with the latest share price sitting around $57.31 and recent 90 day share price returns in negative territory, Altria’s 1 year and multi year total shareholder returns suggest patient investors are still being well rewarded as smoke free momentum gradually builds.
If you like the idea of income plus potential rerating stories, this could also be a good moment to explore pharma stocks with solid dividends as possible additions to your watchlist.
With the shares trading at a modest discount to analyst targets and a far steeper gap to some intrinsic value estimates, the real question now is whether Altria is genuinely undervalued or if the market is already pricing in its smoke free growth.
Most Popular Narrative Narrative: 10.2% Undervalued
With Altria closing at $57.31 against a most-followed fair value of $63.83, the narrative leans toward upside as earnings durability meets constrained growth.
The analysts have a consensus price target of $58.538 for Altria Group based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $73.0, and the most bearish reporting a price target of just $49.0.
Want to see what justifies a higher fair value when revenues barely grow and margins slip? The narrative leans on disciplined buybacks, steady profitability, and a rerating that rivals growth names. Curious how those ingredients mix into today’s discounted cash flows using a sub 10% hurdle rate? Follow through to uncover the full valuation playbook.
Result: Fair Value of $63.83 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upside narrative could unravel if regulatory pressures intensify or if illicit and synthetic nicotine products erode Altria’s share in key growth categories.
Find out about the key risks to this Altria Group narrative.
Build Your Own Altria Group Narrative
If you see the story differently or simply prefer to dig into the numbers yourself, you can build a custom view in under three minutes: Do it your way.
A great starting point for your Altria Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Ready for more investment ideas?
Before you move on, lock in your next smart move by using the Simply Wall Street Screener to uncover fresh opportunities that most investors are still overlooking.
- Capture potential mispricings by scanning these 875 undervalued stocks based on cash flows that look cheap on cash flow, but strong on fundamentals and long term prospects.
- Ride powerful innovation waves by targeting these 25 AI penny stocks that could reshape entire industries with scalable, data driven business models.
- Strengthen your income stream by selecting these 14 dividend stocks with yields > 3% offering resilient payouts that can support returns through changing market cycles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com